Thoraflex™ Hybrid IDE Study
Aortic Aneurysm, Aortic Dissection, Aortic Rupture
About this trial
This is an interventional treatment trial for Aortic Aneurysm focused on measuring Thoracic Surgery, Aortic Arch, Frozen Elephant Trunk, Performance Goal
Eligibility Criteria
Inclusion Criteria:
Main Study Group (All patients except Aortic Rupture Patients)
- Patient is aged 18 years or over on date of consent
- Patient is willing and able to comply with all study procedures and study visits
- Patient or their legally authorized representative has given written informed consent to participate in study
- Patient satisfies the inclusion criteria for one of the following categories:
A - Patient has acute dissection of the aorta or B - Patient has chronic dissection of the aorta or C - Patient has an aortic aneurysm (including connective tissue disorders)
A. - Patients with acute dissection of the aorta:
•Patient has acute aortic dissection and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires replacement, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta.
B. - Patients with chronic dissection of the aorta:
•Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta due to chronic dissection.
And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year (including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement
C. - Patients with an aortic aneurysm (including connective tissue disorders):
•Patient requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta
And patient satisfies one or more of the following criteria:
- Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter ≥5.5cm (including if asymptomatic) or
- Patient has aorta diameter <5.5cm and growth rate ≥0.5cm/year(including if asymptomatic) or
- Patient has ascending aorta diameter ≥4.5cm and requires valve repair or replacement or
- Patient has Marfan syndrome or other genetically mediated disorders with aortic sinus, or ascending aorta, or arch diameter ≥4.5cm, or, the ratio of the maximal ascending or aortic root area (Π r2) in cm2 divided by the patient's height in meters exceeds 10
Inclusion criteria for Patients with Ruptured Aorta only:
- Patient is aged 18 years or over, on date of consent
- Patient or their legally authorized representative is able and willing to give consent to the patient's enrolment in the study
- Patient has either a ruptured thoracic aorta, or, in the experience of the treating surgeon, is at high risk of imminent rupture of the thoracic aorta
Exclusion Criteria:
Main Study Group (All Patients Except Patients with Ruptured Aorta)
- Patient is unfit for open surgical repair involving circulatory arrest
- Patient has known sensitivity to polyester, nitinol or materials of bovine origin
- Patient has a ruptured aorta
- Patient has active endocarditis or an active infective disorder of the aorta
- Patient has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure
- Patient is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study
- Patient is female and is pregnant, or planning to become pregnant during the course of the study. Females of childbearing potential must use acceptable methods of contraception.
- Patient has an uncorrectable bleeding anomaly
- Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.5mg/dL)
- Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated
- Patient has a co-morbidity causing expected survival to be less than 1 year
- Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre and post procedure
Exclusion criteria for Patients with Ruptured Aorta only:
- Patient has chronic dissection which, in the opinion of the investigator, can be treated electively
- Patient has aneurysmal disease which, in the opinion of the investigator, can be treated electively
Sites / Locations
- Stanford University Medical Center
- Emory Saint Joseph's Hospital
- Northwestern Memorial Hospital
- University of Michigan
- The Mount Sinai Hospital
- Columbia University Medical Center
- NY Presbyterian Weill Cornell
- Cleveland Clinic
- University of Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Presbyterian
- Baylor St. Luke's
- University of Texas Houston- Memorial Hermann Texas Medical Center
Arms of the Study
Arm 1
Experimental
Thoraflex™ Hybrid Device.
Plexus™ 4 and Ante-Flo™ configurations will be included in this study.